Literature DB >> 19864079

Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy.

Rakesh Jalali1, Indranil Mallick, Debnarayan Dutta, Savita Goswami, Tejpal Gupta, Anusheel Munshi, Deepak Deshpande, Rajiv Sarin.   

Abstract

PURPOSE: To present the effect of radiotherapy doses to different volumes of normal structures on neurocognitive outcomes in young patients with benign and low-grade brain tumors treated prospectively with stereotactic conformal radiotherapy (SCRT). METHODS AND MATERIALS: Twenty-eight patients (median age, 13 years) with residual/progressive brain tumors (10 craniopharyngioma, 8 cerebellar astrocytoma, 6 optic pathway glioma and 4 cerebral low-grade glioma) were treated with SCRT to a dose of 54 Gy in 30 fractions over 6 weeks. Prospective neuropsychological assessments were done at baseline before RT and at subsequent follow-up examinations. The change in intelligence quotient (IQ) scores was correlated with various factors, including dose-volume to normal structures.
RESULTS: Although the overall mean full-scale IQ (FSIQ) at baseline before RT remained unchanged at 2-year follow-up after SCRT, one third of patients did show a >10% decline in FSIQ as compared with baseline. Logistic regression analysis demonstrated that patients aged <15 years had a significantly higher chance of developing a >10% drop in FSIQ than older patients (53% vs. 10%, p = 0.03). Dosimetric comparison in patients showing a >10% decline vs. patients showing a <10% decline in IQ revealed that patients receiving >43.2 Gy to >13% of volume of the left temporal lobe were the ones to show a significant drop in FSIQ (p = 0.048). Radiotherapy doses to other normal structures, including supratentorial brain, right temporal lobe, and frontal lobes, did not reveal any significant correlation.
CONCLUSION: Our prospectively collected dosimetric data show younger age and radiotherapy doses to left temporal lobe to be predictors of neurocognitive decline, and may well be used as possible dose constraints for high-precision radiotherapy planning. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19864079     DOI: 10.1016/j.ijrobp.2009.06.025

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  49 in total

Review 1.  Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up.

Authors:  Hermann L Müller
Journal:  Nat Rev Endocrinol       Date:  2010-09-28       Impact factor: 43.330

2.  Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.

Authors:  Birgit Flechl; Michael Ackerl; Cornelia Sax; Karin Dieckmann; Richard Crevenna; Alexander Gaiger; Georg Widhalm; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-29       Impact factor: 4.130

Review 3.  Why avoid the hippocampus? A comprehensive review.

Authors:  Vinai Gondi; Wolfgang A Tomé; Minesh P Mehta
Journal:  Radiother Oncol       Date:  2010-10-20       Impact factor: 6.280

4.  Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.

Authors:  Malin Blomstrand; N Patrik Brodin; Per Munck Af Rosenschöld; Ivan R Vogelius; Gaspar Sánchez Merino; Anne Kiil-Berthlesen; Klas Blomgren; Birgitta Lannering; Søren M Bentzen; Thomas Björk-Eriksson
Journal:  Neuro Oncol       Date:  2012-05-17       Impact factor: 12.300

5.  Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.

Authors:  Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

6.  Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease.

Authors:  Sweta Budyal; Anurag R Lila; Rakesh Jalali; Tejpal Gupta; Rajeev Kasliwal; Varsha S Jagtap; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 7.  Whole brain radiotherapy: Consequences for personalized medicine.

Authors:  Tomáš Kazda; Petr Pospíšil; Hana Doleželová; Radim Jančálek; Pavel Slampa
Journal:  Rep Pract Oncol Radiother       Date:  2013-04-19

8.  Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique.

Authors:  N Patrik Brodin; Per Munck af Rosenschöld; Malin Blomstrand; Anne Kiil-Berthlesen; Christian Hollensen; Ivan R Vogelius; Birgitta Lannering; Søren M Bentzen; Thomas Björk-Eriksson
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

9.  Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study.

Authors:  Kristin J Redmond; E Mark Mahone; Stephanie Terezakis; Omar Ishaq; Eric Ford; Todd McNutt; Lawrence Kleinberg; Kenneth J Cohen; Moody Wharam; Alena Horska
Journal:  Neuro Oncol       Date:  2013-01-14       Impact factor: 12.300

Review 10.  Neurocognitive function after radiotherapy for paediatric brain tumours.

Authors:  Laetitia Padovani; Nicolas André; Louis S Constine; Xavier Muracciole
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.